You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Moodys
McKesson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,534,233

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,534,233
Title:Nucleic acid construct and use of the same
Abstract: The present invention is related to a nucleic acid construct comprising an expression unit for the expression of E1B, wherein the expression unit comprises a promoter, a nucleotide sequence coding for E1B, and a 3\'UTR, wherein the promoter is operatively linked to the nucleotide sequence coding for E1B, wherein the 3\'UTR comprises 30 or less than 30 Exonic Enhancer Elements (ESEs), preferably 20 or less than 20 Exonic Enhancer Elements (ESEs), and wherein the 3\' UTR is a non-viral 3\' UTR.
Inventor(s): Kochanek; Stefan (Ulm, DE), Lucas; Tanja (Regensburg, DE), Kueppers; Claudia (Weil am Rhein, DE)
Assignee: Kochanek; Stefan (Ulm, DE)
Application Number:14/395,589
Patent Claims:1. A nucleic acid construct comprising (i) an expression unit for the expression of E1 B, wherein the expression unit comprises a promoter, a nucleotide sequence coding for E1 B, and a 3' UTR, wherein the promoter is operatively linked to the nucleotide sequence coding for E1 B, wherein the 3' UTR comprises 30 or fewer than 30 Exonic Splicing Enhancer elements (ESEs), and wherein the 3' UTR is a non-viral 3' UTR, and (ii) an expression unit for the expression of E1A, wherein the expression unit comprises a promoter, a nucleotide sequence coding for E1A, and a 3' UTR, wherein the promoter is operatively linked to the nucleotide sequence coding for E1A, wherein the expression unit for the expression of E1A and the expression unit for the expression of EIB form a combined expression unit, wherein the combined expression unit comprises the nucleotide sequence of SEQ ID NO: 9 or SEQ ID NO: 15.

2. The nucleic acid construct of claim 1, wherein the 3' UTR comprises 20 or fewer than 20 Exonic Splicing Enhancer elements (ESEs).

3. The nucleic acid construct of claim 1, wherein the nucleic acid construct is a single nucleic acid molecule comprising both the expression unit for the expression of E1A and the expression unit for the expression of E1 B.

4. The nucleic acid construct according to claim 1, wherein the Exonic Splicing Enhancer elements (ESEs) are contained within a stretch of nucleotides of the 3' UTR of the expression unit for the expression of E1 B, and wherein said stretch of nucleotides comprises the 200 nucleotides of the 5' end of the 3' UTR of the expression unit for the expression of E1 B.

5. The nucleic acid construct according to claim 1, wherein the 3' UTR of the expression unit for the expression of E1 B is a mammalian 3' UTR.

6. The nucleic acid construct according to claim 1, wherein the expression unit for the expression of E1A and the expression unit for the expression of E1 B are arranged in a 5'->3' direction in the nucleic acid construct as follows: the promoter of the expression unit for the expression of E1A, the nucleotide sequence coding for E1A and the 3' UTR, the promoter of the expression unit for the expression of E1 B, the nucleotide sequence coding for E1 B, a splice donor site, an intron, a splice acceptor site and the 3' UTR.

7. The nucleic acid construct according to claim 1, wherein the nucleic acid construct is coding for and capable of expressing E1A, E1 B 55K, E1 B 19K and/or E1 B 84R.

8. The nucleic acid construct according to claim 7, wherein the nucleic acid construct is capable of expressing E1A, E1 B 55K, and E1 B 19K.

9. A vector comprising the nucleic acid construct according to claim 1.

10. A cell comprising a the vector according to claim 9.

11. The cell according to claim 10, wherein the cell is an amniocytic cell line.

12. The nucleic acid construct according to claim 7, wherein the nucleic acid construct is capable of expressing E1A, E1 B 55 K, E1 B 19 K and E1 B 84R.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
12003564May 7, 2012
PCT Information
PCT FiledMay 07, 2013PCT Application Number:PCT/EP2013/001356
PCT Publication Date:November 14, 2013PCT Publication Number:WO2013/167265

Details for Patent 9,534,233

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Kochanek; Stefan (Ulm, DE) 2032-05-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Kochanek; Stefan (Ulm, DE) 2032-05-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Kochanek; Stefan (Ulm, DE) 2032-05-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.